Makavos 2020.

Methods	RCT, active‐controlled, open trial Date of study: not stated Setting: not stated
Participants	Randomised: 150 participants, mean age 52; 92 men Inclusion criteria Plaque‐type psoriasis (n = 78) Psoriatic arthritis (n = 72) Exclusion criteria Ejection fraction ≤ 50% history of acute coronary syndrome familial hyperlipidaemia diabetes mellitus moderate‐to‐severe valvular heart disease primary cardiomyopathies malignant tumours Dropouts and withdrawals Not stated
Interventions	Intervention A. Secukinumab, 300 mg SC, W0, 1, 2, 3, 4 and 300 mg once monthly Control intervention B. Ciclosporin, 2.5 to 3 mg/Kg daily C. Methotrexate (non‐randomised controlled group, n = 50)
Outcomes	Assessments at 16 weeks Primary outcome vascular function Secondary outcomes coronary flow reserve of the LAD by doppler echography Arterial stiffness PASI
Notes	Authors were asked whether ‐ methotrexate group was randomised or not ‐ Included patients were moderate‐to‐severe psoriasis ‐ randomisation was stratified according psoriatic arthritis or not ‐ subgroup results for plaques psoriasis for our outcomes